KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Change in Working Capital (2016 - 2017)

Historic Change in Working Capital for Teva Pharmaceutical Industries (TEVA) over the last 8 years, with Q4 2017 value amounting to -$890.0 million.

  • Teva Pharmaceutical Industries' Change in Working Capital fell 84789.92% to -$890.0 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$1.6 billion, marking a year-over-year decrease of 23494.67%. This contributed to the annual value of $1.4 billion for FY2025, which is 21402.3% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Change in Working Capital stood at -$890.0 million for Q4 2017, which was down 84789.92% from -$44.0 million recorded in Q3 2017.
  • Teva Pharmaceutical Industries' 5-year Change in Working Capital high stood at $1.2 billion for Q2 2013, and its period low was -$890.0 million during Q4 2017.
  • Moreover, its 5-year median value for Change in Working Capital was $89.5 million (2013), whereas its average is $90.7 million.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Change in Working Capital skyrocketed by 78426.97% in 2015, and later tumbled by 84789.92% in 2017.
  • Over the past 5 years, Teva Pharmaceutical Industries' Change in Working Capital (Quarter) stood at $359.0 million in 2013, then soared by 41.23% to $507.0 million in 2014, then tumbled by 57.2% to $217.0 million in 2015, then plummeted by 45.16% to $119.0 million in 2016, then tumbled by 847.9% to -$890.0 million in 2017.
  • Its last three reported values are -$890.0 million in Q4 2017, -$44.0 million for Q3 2017, and -$248.0 million during Q2 2017.